Blue Cross Blue Shield · AAT Augmentation · US health-plan appeal rights

AAT Augmentation denied for failing step therapy by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield AAT Augmentation denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for aat augmentation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS Specialty Pharmacy — AAT Augmentation (Prolastin-C / Glassia / Aralast NP / Zemaira)

The Blue Cross Blue Shield angle on AAT Augmentation

## Why BCBS Applies Step Therapy to AAT Augmentation

Step therapy (also called "fail-first") requires that a patient try one or more lower-cost treatments before the plan will approve the prescribed therapy. For AAT augmentation, a step-therapy denial is often a coverage-policy error or a misapplication of criteria, because AAT augmentation is the only pharmacological therapy specifically indicated for the underlying genetic deficiency — there is no therapeutically equivalent "step" drug. However, BCBS policies may require documentation that general COPD therapies (bronchodilators, inhaled corticosteroids) were tried and were insufficient before augmentation is approved.

## Why This Is Appealable

Many states have enacted step-therapy override laws requiring insurers to waive step requirements when (a) the required step drug is contraindicated or clinically inappropriate for the patient, (b) the patient has already tried and failed the required step, or (c) the step drug is not therapeutically equivalent to the prescribed drug. For a condition with a specific genetic cause and a specifically indicated therapy, argument (c) is often the strongest. ACA §2719 and ERISA §503 provide the federal appeal framework; state law may add additional protections. External review is available within 4 months of a final internal denial.

## Documentation to Gather

Prior treatment history: A chronological list of all bronchodilators, inhaled therapies, and other respiratory medications tried, with start/stop dates and documented clinical outcomes (exacerbation rates, PFT trends, hospitalizations).
Physician letter on therapeutic distinctness: A letter from the treating pulmonologist or AAT specialist explaining why AAT augmentation addresses the specific pathophysiological mechanism of the condition in a way that no required step drug does.
Diagnosis confirmation: Laboratory phenotype/genotype documentation confirming hereditary AAT deficiency (not simply COPD), establishing that this is a distinct condition from generic obstructive lung disease.
State step-therapy override law reference: If your state has a step-therapy override statute, your physician's letter should cite the applicable override ground (contraindication, prior failure, or therapeutic non-equivalence).

## Criteria-Mapping Structure

Obtain BCBS's step-therapy policy for this drug from its clinical policy bulletin. List each required step in the left column. In the right column, document either (a) the date you tried that step and the documented outcome, or (b) the clinical reason why that step is not therapeutically equivalent or is inappropriate. Reference the FDA prescribing label's approved indication to demonstrate the distinction between AAT augmentation and general COPD therapies.

## Timeline

1. File internal appeal within 180 days of denial. 2. If state step-therapy override law applies, cite it in your appeal letter. 3. Standard internal appeal decision: 30 days (pre-service). 4. After final internal denial: request external review within 4 months.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield AAT Augmentation

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.